Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Early-Stage Breast Carcinoma|Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma
Interventions: DRUG: Celecoxib|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Doxorubicin Hydrochloride|DRUG: Paclitaxel|BIOLOGICAL: Recombinant Interferon Alfa-2b|DRUG: Rintatolimod
Sponsor: Roswell Park Cancer Institute
Collaborators: National Center for Advancing Translational Sciences (NCATS)